В-клеточная лимфома неклассифицируемая с промежуточными признаками между диффузной крупноклеточной в-клеточной лимфомой и лимфомой Ходжкина

В-клеточная лимфома неклассифицируемая с промежуточными признаками между диффузной крупноклеточной В-клеточной лимфомой и лимфомой Ходжкина (НВКЛ) - редкая агрессивная лимфома с неопределенным прогнозом, имеющая специфические морфологические и иммунофенотипические характеристики, свойственные как диффузной В-крупноклеточной лимфоме, так и лимфоме Ходжкина. В статье представлены сравнительные характеристики НВКЛ и различных вариантов крупноклеточных В-клеточных лимфом, а также описание клинического случая НВКЛ у ребенка 3 лет. Родители пациента дали согласие на использование информации о нем, в том числе фотографий, в научных исследованиях и публикациях.

1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. editors. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues. Lyon. 2008.

2. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-90.

3. Traverse-Glehen A., Pittaluga S., Gau-lard P., Sorbara L., Alonso M.A., Raffeld M., et al. Mediastinal gray zone lymphoma: themis sing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J SurgPathol 2005; 29 (11): 1411-21.

4. Aukema S.M., Siebert R., Schuuring E., van Imhoff G.W., Kluin-Nelemans H.C., Boerma E.J., et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-31.

5. Martelli M., Ceriani L., Zucca E., Zin-zani P.L., Ferreri A.J., Vitolo U., et al. fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014; 32 (17): 1769-75.

6. Belgaumi A., Al-Kofide A., Joseph N., Jamil-Malik R., Khafaga Y., Sab-bah R. Hodgkin lymphoma in very young children: Clinical characteristic sand outcome of treatment. Leuk Lymphoma 2008; 49 (5): 910-6.

7. Sharp L., Cotton S., Little J. Descriptive epidemiology. In: Epidemiology of childhood cancer. Edited by Little J. Lyon (IARC Scientific Publications No. 149). France: IARC Press, 1999: 10-66.

8. Clavel J., Steliarova-Foucher E., Berger C., Danon S., Zdravka G.V. Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. Eur J Cancer 2006; 42 (13): 2037-49.

9. Cazals-Hatem D., Lepage E., Brice P., Ferrant A., d'Agay M.F., Baumelou E., et al. Primary mediastinal large B-cell lymphoma. A clinic pathologic study of 141 cases compared with 916 non mediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996; 20 (7): 877-88.

10. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B - cell lymphoma identify es a clinically favorable subgroup of diff use large B - cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198 (6): 851-62.

11. Paulli M., Strater J., Gianelli U., Rousset M.T., Gambacorta M., Orlandi E., et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 1999; 30 (2): 178-87.

12. Kanavaros P., Gaulard P., Charlotte F., Martin N., Ducos C., Lebezu M., et al. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B-cell lymphomas. Am J Pathol 1995; 146 (3): 735-41.

13. Higgins J.P., Warnke R.A. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999; 112: 241-7.

14. Eberle F.C., Salaverria I., Steidl C., Summers T.A.Jr, Pittaluga S., Neriah S.B., et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol 2011; 24 (12): 1586-97.

15. Feuerhake F., Kutok J.L., Monti S., Chen W., LaCasce A.S., Cattoretti G., et al. NFkappa B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diff use large B-cell lymphoma subtypes. Blood 2005; 106 (4): 1392-9.

16. Zhang B., Wang Z., Li T., Tsitsikov E.N., Han-Fei D. NF-kappa B 2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007; 110 (2): 743-51.

17. Rossi D., Cerri M., Capello D., Deam-brogi C., Berra E., Franceschetti S., et al. Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. Leukemia 2005; 19 (12): 2363-6.

18. Sarkozy С., Thierry M., Ghesquieres Н., Michallet A.S., Dupuis J., Damotte D., et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 2017 Jan; 102 (1): 150-9.

19. Melani C., Major A., Schowinsky J., Roschewski M., Pittaluga S., Jaffe E.S., et al. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med 2017 Jul 6; 377 (1): 89-91.

20. Kharfan-Dabaja M.A., Raj R., Nikolaenko L., Ahmed S., Reddy N., Nathan S.E., et al. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant 2018 Mar; 24 (3): 486-93.